Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AU
Aura Biosciences, Inc. Common Stock
AURA
Mkt Cap
$633.1M
Volume
652.94K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AU
AURA
AU
Aura Biosciences, Inc. Common Stock
AURA
News
·
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mkt Cap
$657.5M
Volume
652.94K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards granted to newly appointed Chief Executive Officer and President Natalie Holles on May 19, 2026. The awards include stock options for 2.17 million shares at $7.39 exercise price, 600,118 RSUs, and 553,844 performance-based RSUs with multi-year vesting schedules. The grants align with previously disclosed terms of her offer letter and were approved by the Board in accordance with Nasdaq regulations.
GlobeNewswire Inc. · May 19, 2026
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences, a clinical-stage biotechnology company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, discussing their precision therapies for solid tumors.
GlobeNewswire Inc. · Sep 3, 2025
Aura Biosciences Posts Q2 Cash Surge
Aura Biosciences reported Q2 2025 financial results, highlighting continued clinical development of bel-sar for ocular and bladder cancers, raising $75 million in equity, and maintaining a cash runway into early 2027.
The Motley Fool · Aug 13, 2025
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported Q2 2025 financial results, highlighting ongoing clinical trials for bel-sar in early choroidal melanoma and non-muscle invasive bladder cancer. The company raised $75 million in equity financing and expects cash to fund operations into the first half of 2027.
GlobeNewswire Inc. · Aug 13, 2025
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Aura Biosciences announced the pricing of a public offering of common stock and warrants, raising $75 million. The company plans to use the proceeds to advance its clinical programs in various cancer indications.
Benzinga · May 15, 2025
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Aura Biosciences, a clinical-stage biotechnology company, announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to its Board of Directors. Bitetti's extensive operational and commercial experience will be valuable as Aura advances its clinical pipeline in ocular and urologic oncology.
GlobeNewswire Inc. · Apr 2, 2025
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura Biosciences announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of non-muscle invasive bladder cancer will be presented at the European Association of Urology Congress. The company will also host a virtual investor event to discuss the data and provide a program update.
GlobeNewswire Inc. · Mar 3, 2025
3 Small-Cap Stocks Ready to Deliver Significant Growth
The article discusses three small-cap stocks that are poised for significant growth due to the Federal Reserve's recent interest rate cuts, which are expected to benefit small-cap companies that rely heavily on debt to fuel their growth.
Benzinga · Oct 15, 2024
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
Zacks Investment Research · Jul 1, 2024
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Zacks Investment Research · Jun 25, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AU
AURA
Aura Biosciences, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
AURA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AURA yet.
Related Tickers
Earnings